Search Results for "Hypertension"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Hypertension. Results 371 to 380 of 398 total matches.

Comparison Table: Some Drugs for HFrEF (online only)

   
The Medical Letter on Drugs and Therapeutics • Mar 08, 2021  (Issue 1619)
other distribution of this material is strictly prohibited. 10 Symptomatic bradycardia, hypertension, atrial ...
View the Comparison Table: Some Drugs for HFrEF
Med Lett Drugs Ther. 2021 Mar 8;63(1619):e1-14 |  Show IntroductionHide Introduction

Drugs for Stable Angina Pectoris

   
The Medical Letter on Drugs and Therapeutics • Dec 09, 1994  (Issue 937)
of choice for patients with both angina and hypertension who have contraindications to treatment ...
Many nitrates, beta-blockers, and calcium-channel blockers have now been approved by the US Food and Drug Administration for treatment of stable angina pectoris. The table beginning on page 112 lists the individual drugs, their dosage, and their cost.
Med Lett Drugs Ther. 1994 Dec 9;36(937):111-4 |  Show IntroductionHide Introduction

Omadacycline (Nuzyra) - A New Tetracycline Antibiotic

   
The Medical Letter on Drugs and Therapeutics • May 20, 2019  (Issue 1572)
, diarrhea, constipation, headache, hypertension, insomnia, and hepatic transaminase elevations. Nausea ...
The FDA has approved omadacycline (Nuzyra – Paratek), a semisynthetic tetracycline derivative, for once-daily IV and oral treatment of community-acquired bacterial pneumonia (CAP) and acute bacterial skin and skin structure infections (ABSSSIs) in adults.
Med Lett Drugs Ther. 2019 May 20;61(1572):74-7 |  Show IntroductionHide Introduction

Prevention and Treatment of Injury from Chemical Warfare Agents

   
The Medical Letter on Drugs and Therapeutics • Jan 07, 2002  (Issue 1121)
or IM. IV doses should be given over 20-30 minutes to prevent hypertension. Pralidoxime can be repeated ...
The recent terrorist attacks on the US have led to many questions about the clinical effects, prevention and treatment of injury caused by chemical warfare agents.
Med Lett Drugs Ther. 2002 Jan 7;44(1121):1-4 |  Show IntroductionHide Introduction

Drugs for Rheumatoid Arthritis

   
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021  (Issue 1637)
occurs frequently with leflunomide. Reversible alopecia, rash, hypertension, myelosuppression ...
Rheumatoid arthritis (RA) is prevalent in 0.5% of adults in the US; it is about 2.5 times more common in women than in men. Guidelines for treatment of RA from the American College of Rheumatology were recently updated. The goal of treatment is to minimize disease activity and prevent irreversible joint damage.
Med Lett Drugs Ther. 2021 Nov 15;63(1637):177-84 |  Show IntroductionHide Introduction

Drugs for GERD and Peptic Ulcer Disease

   
The Medical Letter on Drugs and Therapeutics • Apr 04, 2022  (Issue 1647)
. Tetracyclines can cause GI adverse effects, vaginal candidiasis, photosensitivity, intracranial hypertension ...
Gastroesophageal reflux disease (GERD) is the most common GI condition encountered in the outpatient setting; it affects about 20% of people in the US.
Med Lett Drugs Ther. 2022 Apr 4;64(1647):49-56 |  Show IntroductionHide Introduction

In Brief: One Drop or Two

   
The Medical Letter on Drugs and Therapeutics • Jun 19, 2006  (Issue 1237)
, thirst, hypokalemia, hypertension, vomiting, diarrhea and orthostatic hypotension have occurred in more ...
Many prescriptions for eye drops call for instillation of 1-2 drops. But Medical Letter consultants in ophthalmology seem to agree that all eye drops should generally be given in doses of only one drop. The volume of a single drop can vary with the viscosity of the solution, the design of the dropper, and patient technique. The average volume of a drop is 35-50 microliters, but can be as high as 75 microliters. An eye brimming with fluid holds 30 microliters at best, so even one drop is often an overdose. A second either washes out the first or increases the possibility of systemic toxicity,...
Med Lett Drugs Ther. 2006 Jun 19;48(1237):49 |  Show IntroductionHide Introduction

Clopidogrel (Plavix) Revisited

   
The Medical Letter on Drugs and Therapeutics • Apr 10, 2006  (Issue 1232)
with aspirin alone in patients with multiple atherothrombotic risk factors (diabetes, hypertension, etc ...
Clopidogrel (Plavix - Sanofi-Aventis and Bristol-Myers Squibb), an oral thienopyridine that inhibits platelet aggregation, is now being advertised directly to the public on television. Clopidogrel is approved by the FDA for secondary prevention of myocardial infarction (MI), stroke and other vascular events and for use in patients with acute coronary syndrome (unstable angina or non-ST-elevation MI), including those undergoing angioplasty. It is used off-label for patients with ST-elevation acute MI
Med Lett Drugs Ther. 2006 Apr 10;48(1232):29-31 |  Show IntroductionHide Introduction

Rasagiline (Azilect) for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • Dec 04, 2006  (Issue 1249)
during treatment and for 14 days after rasagiline is discontinued to avoid a possible hypertensive ...
Rasagiline (Azilect - Teva), a monoamine oxidase-type B (MAO-B) inhibitor, was recently approved by the FDA for once-daily oral treatment of Parkinson's disease (PD). It can be taken alone for treatment of early disease or with levodopa/carbidopa (Sinemet, and others) for advanced disease. Selegiline (Eldepryl, and others), the first MAO-B inhibitor marketed in the US, has been available since 1988; a new lower-dose disintegrating tablet (Zelapar) was recently approved.
Med Lett Drugs Ther. 2006 Dec 4;48(1249):97-9 |  Show IntroductionHide Introduction

Drugs for Acne

   
The Medical Letter on Drugs and Therapeutics • Feb 05, 2024  (Issue 1695)
, intracranial hypertension, and hyperpigmentation. CNS effects such as dizziness and vertigo can occur ...
Acne is common among adolescents and adults. Guidelines for treatment of acne were last published by the American Academy of Dermatology in 2016.
Med Lett Drugs Ther. 2024 Feb 5;66(1695):17-20   doi:10.58347/tml.2024.1695a |  Show IntroductionHide Introduction